Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported EBIT over the past 12 years, most recently at -$122.7 million for Q4 2025.

  • Quarterly results put EBIT at -$122.7 million for Q4 2025, down 40.33% from a year ago — trailing twelve months through Dec 2025 was -$363.4 million (down 21.52% YoY), and the annual figure for FY2025 was -$363.4 million, down 21.52%.
  • EBIT for Q4 2025 was -$122.7 million at Viridian Therapeutics, Inc.\DE, down from -$40.0 million in the prior quarter.
  • Over the last five years, EBIT for VRDN hit a ceiling of -$14.1 million in Q3 2021 and a floor of -$122.7 million in Q4 2025.
  • Median EBIT over the past 5 years was -$53.6 million (2023), compared with a mean of -$56.5 million.
  • Peak annual rise in EBIT hit 67.9% in 2021, while the deepest fall reached 182.37% in 2021.
  • Viridian Therapeutics, Inc.\DE's EBIT stood at -$29.1 million in 2021, then tumbled by 68.72% to -$49.1 million in 2022, then crashed by 45.68% to -$71.5 million in 2023, then decreased by 22.38% to -$87.5 million in 2024, then plummeted by 40.33% to -$122.7 million in 2025.
  • The last three reported values for EBIT were -$122.7 million (Q4 2025), -$40.0 million (Q3 2025), and -$106.8 million (Q2 2025) per Business Quant data.